Terms: = Sarcomas AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA
18 results:
1. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.
van Weelden WJ; Birkendahl PB; Lalisang RI; IntHout J; Kruitwagen RFPM; Romano A; Pijnenborg JMA
BJOG; 2023 Jan; 130(2):143-152. PubMed ID: 36264251
[TBL] [Abstract] [Full Text] [Related]
2. Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults.
Yoshida A; Arai Y; Hama N; Chikuta H; Bando Y; Nakano S; Kobayashi E; Shibahara J; Fukuhara H; Komiyama M; Watanabe SI; Tamura K; Kawai A; Shibata T
Histopathology; 2020 Mar; 76(4):509-520. PubMed ID: 31647130
[TBL] [Abstract] [Full Text] [Related]
3. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract] [Full Text] [Related]
4. IRF-4-mediated ciita transcription is blocked by KSHV encoded LANA to inhibit MHC II presentation.
Cai Q; Banerjee S; Cervini A; Lu J; Hislop AD; Dzeng R; Robertson ES
PLoS Pathog; 2013 Oct; 9(10):e1003751. PubMed ID: 24204280
[TBL] [Abstract] [Full Text] [Related]
5. Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.
Zuo J; Hislop AD; Leung CS; Sabbah S; Rowe M
J Virol; 2013 May; 87(10):5340-50. PubMed ID: 23449805
[TBL] [Abstract] [Full Text] [Related]
6. Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.
Butler LM; Jeffery HC; Wheat RL; Long HM; Rae PC; Nash GB; Blackbourn DJ
J Virol; 2012 Jul; 86(13):7158-66. PubMed ID: 22532676
[TBL] [Abstract] [Full Text] [Related]
7. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee.
Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D
Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650
[TBL] [Abstract] [Full Text] [Related]
8. ciita is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.
Londhe P; Zhu B; Abraham J; Keller C; Davie J
Int J Cancer; 2012 Aug; 131(4):E437-48. PubMed ID: 21989738
[TBL] [Abstract] [Full Text] [Related]
9. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression.
Schmidt K; Wies E; Neipel F
J Virol; 2011 May; 85(9):4530-7. PubMed ID: 21345951
[TBL] [Abstract] [Full Text] [Related]
10. ciita-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
[TBL] [Abstract] [Full Text] [Related]
11. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.
Berghuis D; de Hooge AS; Santos SJ; Horst D; Wiertz EJ; van Eggermond MC; van den Elsen PJ; Taminiau AH; Ottaviano L; Schaefer KL; Dirksen U; Hooijberg E; Mulder A; Melief CJ; Egeler RM; Schilham MW; Jordanova ES; Hogendoorn PC; Lankester AC
J Pathol; 2009 Jun; 218(2):222-31. PubMed ID: 19274709
[TBL] [Abstract] [Full Text] [Related]
12. Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator.
Boye K; Andersen K; Tveito S; Øyjord T; Maelandsmo GM
Tumour Biol; 2007; 28(1):27-35. PubMed ID: 17143014
[TBL] [Abstract] [Full Text] [Related]
13. Collagen alpha1(I) gene (COL1A1) is repressed by RFX family.
Sengupta P; Xu Y; Wang L; Widom R; Smith BD
J Biol Chem; 2005 Jun; 280(22):21004-14. PubMed ID: 15788405
[TBL] [Abstract] [Full Text] [Related]
14. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA.
Han Y; Zhou ZH; Ransohoff RM
J Immunol; 1999 Aug; 163(3):1435-40. PubMed ID: 10415044
[TBL] [Abstract] [Full Text] [Related]
15. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
Armstrong TD; Clements VK; Martin BK; Ting JP; Ostrand-Rosenberg S
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6886-91. PubMed ID: 9192661
[TBL] [Abstract] [Full Text] [Related]
16. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression.
Lee YJ; Han Y; Lu HT; Nguyen V; Qin H; Howe PH; Hocevar BA; Boss JM; Ransohoff RM; Benveniste EN
J Immunol; 1997 Mar; 158(5):2065-75. PubMed ID: 9036950
[TBL] [Abstract] [Full Text] [Related]
17. Residue Trp-48 of Tva is critical for viral entry but not for high-affinity binding to the SU glycoprotein of subgroup A avian leukosis and sarcoma viruses.
Zingler K; Young JA
J Virol; 1996 Nov; 70(11):7510-6. PubMed ID: 8892869
[TBL] [Abstract] [Full Text] [Related]
18. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract] [Full Text] [Related]
